HHS Issues IG Agenda for Fiscal 2017

The HHS inspector general’s office laid out its agenda for the fiscal year, planning new and expanded reviews of the FDA’s oversight of blood establishments and laboratory-developed diagnostics; management of IT modernization initiatives; and its use of prescription drug user fees.

The office will continue its examination of industry compliance with the Drug Supply Chain Security Act. The office also plans to investigate how much hospitals rely on drug compounders, the large-scale outsourcing facilities that combine pharmaceutical ingredients without patient-specific prescriptions, and are regulated by the FDA.